Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure

Conclusions:
Treatment with olmesartan for 8 weeks does not improve fatty acid oxidation or the activity of enzymes associated with oxidative metabolism in skeletal muscle from overweight and obese individuals. Taken together, our results indicate that improvements in skeletal muscle metabolism are not among the additional benefits of olmesartan that extend beyond blood pressure reduction.

Source: Therapeutic Advances in Cardiovascular Disease - March 3, 2015 Category: Cardiology Authors: Boutagy, N. E., Marinik, E. L., McMillan, R. P., Anderson, A. S., Frisard, M. I., Davy, B. M., Rivero, J. M., Davy, K. P., Hulver, M. W. Tags: Original Research Source Type: research